TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03885908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: in-person geriatric co-management
Description: The geriatrics service sees these patients for at least 2 postoperative days, if deemed clinically necessary by the geriatrician. During the inpatient hospital course, the geriatrics service will ensure the execution of preoperative recommendations and will discuss with the surgical team, who will act as a primary team, any additional recommendation in order to improve postoperative care. In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: automated geriatric co-management
Description: Following completion of the eRFA, the summary of impairments as well as the recommendations generated by the study team (hard-copy or email) will be provided in real-time to the surgery team for their attention.
Study: NCT02204917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPTISON
Description: Contrast enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. Voiding Cystourethrography (VCUG) examination will be subsequently performed as part of the standard care.
Study: NCT00802711

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Given twice a day for 10 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Given twice a day for 10 fractions
Study: NCT03817606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tritanium Posterior Lumbar Cage
Description: Placement of Tritanium Posterior Lumbar Cage via TLIF procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AVS UniLIF PEEK Posterior Lumbar Cage
Description: Placement of AVS UniLIF PEEK Posterior Lumbar Cage via TLIF procedure.
Study: NCT03754114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICP + PbtO2 guided management strategy
Description: In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg and to avoid PbtO2 dropping below 20 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada for patients with severe TBI. The devices are used in standard care at hospitals participating in this research study. Doctors adjust their treatment choices to try to achieve these ICP and PbtO2 goals. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICP guided management strategy
Description: In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull, but PbtO2 is not used to guide care. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada, and are routinely used in patients with severe TBI. Doctors adjust their treatment choices to try to achieve this ICP goal. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
Study: NCT02159508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Description: In both study arms, daily estimated energy requirements were calculated from the basal energy requirements according to WHO multiplied by a 1.5 activity factor and protein requirement (g/day) was calculated multiplying ideal body weight (defined as BMI 22) by 1.2 to 1.5.
Study: NCT02314481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: Intravenous (IV) infusion, as monotherapy of in combination with chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Film coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: capsule
Study: NCT00439972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: extended use of Ortho Evra (R)
Description: The extended use regimen of Ortho Evra (R) contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule for Ortho-Evra (R) is to apply one patch each week for 7 weeks and no patch the 8th week. Extended use Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
Study: NCT00466817

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9 grams of powder which contains no Valganciclovir free base. The oral solution formulation comprises the following excipients: mannitol, lactose anhydrous, fumaric acid, sodium benzoate, saccharin sodium, flavor, and purified water.
Study: NCT02314481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Powder for concentrate for solution for infusion
Study: NCT02695342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home balance exercise program
Study: NCT03435679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one-stage
Description: one-stage surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two-stage
Description: two-stage surgery
Study: NCT00474526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine
Study: NCT00466817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Mono-valyl ester pro-drug of ganciclovir, oral solution, provided as a 12 grams of powder containing 5 grams of Valganciclovir free base. The oral solution formulation comprises the following excipients: Providone K30, fumaric acid, sodium benzoate, sodium saccharin, mannitol, flavor, and purified water.
Study: NCT00474526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV
Study: NCT03217591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1973
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1973
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT01039467

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Adapta Dual Chamber Pacemaker
Description: Medtronic Adapta Dual Chamber Pacemaker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Adapta Dual Chamber Pacemaker
Description: Medtronic Adapta Dual Chamber Pacemaker
Study: NCT03844906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: SAGE-718 in combination with Ketamine
Study: NCT00474526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HBV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib
Study: NCT03844906

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in combination with Ketamine
Study: NCT03575702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uritos®
Description: film-coated tablets 0.1 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urotol®
Description: film coated tablets, 2 mg
Study: NCT03220841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Injection
Description: Standard dose adalimumab induction and maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab Injection
Description: Standard dose adalimumab induction and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiopurine
Description: Dose optimized thiopurine
Study: NCT00474526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib
Study: NCT03220841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilatation
Description: Prior to randomization, suitable patients may undergo endoscopic balloon dilatation. Patients undergoing dilatation will be stratified to ensure equal numbers in each study arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic balloon dilatation
Description: Prior to randomization, suitable patients may undergo endoscopic balloon dilatation. Patients undergoing dilatation will be stratified to ensure equal numbers in each study arm.
Study: NCT03732378

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 capsule
Description: Daily one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given anti depressent( citalopram, escitalopram, paroxetine 1 tablet at night time)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 capsule
Description: Daily one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given anti depressent( citalopram, escitalopram, paroxetine 1 tablet at night time)
Study: NCT00474526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus
Study: NCT03405727

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral dietary supplements
Description: Protein enriched diet
Study: NCT02917174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Asthma Management System
Description: Patients in this group use a smartphone app in their asthma self-management.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: traditional Asthma Management System
Description: Patients in this group use a printed asthma diary in their asthma self-management.
Study: NCT02631447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818 450 mg p.o. od

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818 450 mg p.o. od

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818 450 mg p.o. od

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 45 mg p.o. bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 45 mg p.o. bid
Study: NCT00474526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent Conjugate Vaccine
Study: NCT02631447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 45 mg p.o. bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
Study: NCT00621790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenoldopam
Description: fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00474526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV
Study: NCT00157339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injected insulin
Description: patient specific dose, injected, before meals, 12 months.
Study: NCT03818152

Intervention type: OTHER
Group type: OTHER
Intervention: Functional strength assessment
Description: Functional strength exercises to assess strength in lower limbs.
Study: NCT00474526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV
Study: NCT02785939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV (arm II closed to accrual 12/18/2015)
Study: NCT00474526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV
Study: NCT02785939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00474526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR-V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP
Study: NCT01077453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally
Study: NCT02785939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT03292016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-130277
Description: APL-130277 sublingual thin film

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APO-go
Description: Subcutaneous APO-go